Home Newsfeeds Evercore ISI Group Upgrades Enanta Pharmaceuticals to Outperform, Announces $62 Price Target

Evercore ISI Group Upgrades Enanta Pharmaceuticals to Outperform, Announces $62 Price Target

Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from In-Line to Outperform and announces $62 price target.

byBenzinga Newsdesk

July 6, 2022

1 minute read

Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from In-Line to Outperform and announces $62 price target.

Raymond James Maintains Outperform on PubMatic, Lowers Price Target to $24

By Benzinga Newsdesk

July 26, 5:53 AM

Raymond James analyst Aaron Kessler maintains PubMatic (NASDAQ:PUBM) with a Outperform and lowers the price target from $25 to $24.

PUBM

MeiraGTx Announces $50M Milestone From Janssen Pharmaceuticals

By Benzinga Newsdesk

February 13, 9:09 AM

MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the achievement of the first milestone under the asset purchase agreement the Company entered into

JNJ

News
Tech

Grab Samsung’s Galaxy Tab S9 With Savings Of Up To $770

By Rounak Jain

September 12, 3:31 AM

The Samsung Galaxy Tab S9 is now available at an eye-watering savings of up to $770 on Best Buy, less than a month after its launch.

BBY

Ziff Davis Q4 Adj. EPS $2.26 Misses $2.36 Estimate

By Michael Horton

February 15, 6:53 PM

Ziff Davis (NASDAQ:ZD) reported quarterly earnings of $2.26 per share which missed the analyst consensus estimate of $2.36 by 4.24 percent. This is a 4.15 percent increase over earnings of $2.17 per share from the same

Evercore ISI Group Upgrades Enanta Pharmaceuticals to Outperform, Announces $62 Price Target

Related Posts

Raymond James Maintains Outperform on PubMatic, Lowers Price Target to $24

MeiraGTx Announces $50M Milestone From Janssen Pharmaceuticals

Grab Samsung’s Galaxy Tab S9 With Savings Of Up To $770

Ziff Davis Q4 Adj. EPS $2.26 Misses $2.36 Estimate